On Tuesday, Monsanto Company (NYSE:MON)’s shares declined -0.03% to $116.58.
Monsanto Company (MON) is quietly working with Syngenta AG to iron out regulatory concerns that could stymie its proposed takeover of its Swiss rival, people with knowledge of the situation said.
Antitrust lawyers for the two companies are discussing how to address regulatory hurdles that would arise from the combination, said the people, who asked not to be identified because the talks are private. The efforts don’t guarantee that Monsanto will raise its offer or that an agreement will be reached, the people said.
Syngenta would consider entering formal negotiations if Monsanto sufficiently raises its offer and provides a multibillion-dollar termination fee to compensate for the risks of completing a deal, said the people.
The Swiss firm considers something around 10 percent of the purchase price, which would amount to $4.5 billion at the current bid, as reasonable, one of the people said, though no concrete amount has been set.
Syngenta gained as much as 2.5 percent in Swiss trading, valuing the company at 40 billion francs ($43 billion). The stock has risen 36 percent since Bloomberg on April 30 reported the approach by the U.S. rival. Monsanto’s offer would represent a 43 premium to the price at the time.
Monsanto Company, together with its auxiliaries, provides agricultural products for farmers worldwide. It operates in two segments, Seeds and Genomics, and Agricultural Productivity. The Seeds and Genomics segment produces row crop seeds, counting corn, soybean, cotton, and canola seeds principally under the DEKALB, Channel, Asgrow, and Deltapine brands; and vegetable seeds compriseing of tomato, pepper, melon, cucumber, pumpkin, squash, beans, broccoli, onions, lettuce, and other seeds under the Seminis and De Ruiter brands.
Acorda Therapeutics Inc (NASDAQ:ACOR)’s shares dropped -1.25% to $29.99.
Acorda Therapeutics Inc (ACOR) declared that it has put a hold on a Phase 1b clinical trial of cimaglermin alfa based on the occurrence of a case of hepatotoxicity (liver injury) meeting Hy’s Law criteria (elevated ALT, AST and bilirubin).
There was also one case of hepatotoxicity meeting Hy’s Law criteria stated in the previous Phase 1 clinical trial of cimaglermin, which resolved within several days. The Company has ongoing non-clinical studies to investigate the pathological basis for liver interactions.
The Company plans to review these and other data from the cimaglermin trials with the U.S. Food and Drug Administration (FDA). Following talk aboutions with the FDA, the Company will provide an update on the cimaglermin program.
Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with multiple sclerosis (MS); Zanaflex Capsules and Zanaflex tablets for the administration of spasticity, a symptom of central nervous system disorders; and Qutenza, a dermal patch for the administration of neuropathic pain associated with post-herpetic neuralgia.
At the end of Tuesday’s trade, BreitBurn Energy Partners L.P. (NASDAQ:BBEP)‘s shares dipped -0.19% to $5.31.
BreitBurn Energy Partners L.P. (BBEP) declared recently a cash distribution of $0.04166 per common unit for the third month attributable to the first quarter of 2015, payable on June 12, 2015, to record holders of its common units at the close of business on June 8, 2015. This monthly distribution is equal to a distribution of $0.50 per common unit on an annualized basis.
Breitburn also declared recently distributions for its 8.25% Series A Cumulative Redeemable Perpetual Preferred Units (BBEPP) and 8.0% Series B Perpetual Convertible Preferred Units. A cash distribution of $0.171875 per Series A Unit, is payable on July 15, 2015, to record holders of its Series A Units at the close of business on June 30, 2015. This monthly distribution is equal to an annual distribution of $2.0625 per Series A Unit. Breitburn has elected to pay the distribution on the Series B Units in kind by issuing additional Series B Units instead of paying a cash distribution. A distribution of 0.006666 PIK unit per Series B Unit is payable on June 15, 2015, to record holders of Series B Units at the close of business on May 29, 2015.
Breitburn Energy Partners LP, an independent oil and gas partnership, acquires, exploits, and develops oil, natural gas liquids (NGLs), and natural gas properties in the United States. The company’s oil, NGL, and natural gas reserves are primarily located in seven producing areas comprising the Arkansas, Louisiana, and East Texas; Michigan, Indiana, and Kentucky; Permian Basin in Texas and New Mexico; the Mid-Continent covering Oklahoma, Kansas, and the Texas Panhandle; Rockies in Wyoming; Florida and Alabama; and California.
Northern Trust Corporation (NASDAQ:NTRS), ended its Tuesday’s trading session with 0.20% gain, and closed at $74.40.
Northern Trust Corporation (NTRS) declared it has established a registered investment advisor partner, 50 South Capital Advisors, LLC. Formed from the Northern Trust Alternatives Group, the investment boutique will provide investors with customized solutions through its access to unique and differentiated private equity and hedge fund managers in the small- and mid-market segments.
Northern Trust Corporation, a financial holding company, provides asset servicing, fund administration, asset administration, fiduciary, and banking solutions for corporations, institutions, families, and individuals worldwide. It operates in two segments, Corporate & Institutional Services (C&IS) and Wealth Administration.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
